Comparative

OMIA group 1271

Dwarfism, ACAN-related

The chain reaches the human disease short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans, which Mondo defines as: “A rare genetic skeletal disorder characterized clinically by abnormal chondro-skeletal development, disproportionate short stature and skeletal deformation mainly affecting the knees, hips, ankles and elbows with onset generally in late childhood or adolescence.” It reaches 2 more human diseases, listed below.

The chain

From the animal disease to the drugs. The page shows what each step found and where the chain stopped. It does not say whether the animal is a model of a human disease.

  1. Animal disease

    Reached

    OMIA records it in 3 species entries marked as a defect.

  2. Human disease

    Reached

    3 Mondo diseases.

  3. Human gene

    Reached

    1 human gene.

  4. Target evidence

    Reached

    2 Open Targets associations, with a best score of 0.75.

  5. Drugs

    Stopped here

    No ChEMBL drug acts on a human gene of the group's target evidence.

The chain stopped at Drugs: No ChEMBL drug acts on a human gene of the group's target evidence.

Natural-model score

How complete and how well supported the chain to each human disease is, out of 100, by stated rules. It does not say that the animal is a validated model of the human disease. How the score works.

Part Computed from Points
Target evidence Open Targets score of 0.75 26.3 of 35
Drugs No drug has been tested for this disease, and none acts on its genes 0.0 of 25
Ortholog One to one ortholog 20.0 of 20
Both routes One route found this disease 5.0 of 10
Species 3 naturally occurring species entries marked as a defect 10.0 of 10
Part Computed from Points
Target evidence Open Targets score of 0.74 25.9 of 35
Drugs No drug has been tested for this disease, and none acts on its genes 0.0 of 25
Ortholog One to one ortholog 20.0 of 20
Both routes One route found this disease 5.0 of 10
Species 3 naturally occurring species entries marked as a defect 10.0 of 10
Part Computed from Points
Target evidence No Open Targets association with this disease 0.0 of 35
Drugs No drug has been tested for this disease, and none acts on its genes 0.0 of 25
Ortholog One to one ortholog 20.0 of 20
Both routes One route found this disease 5.0 of 10
Species 3 naturally occurring species entries marked as a defect 10.0 of 10

Species

The chain follows only the species entries that OMIA marks as a defect.

Species Scientific name OMIA entry A defect
domestic cattle Bos taurus OMIA:001271-9913 Yes
horse Equus caballus OMIA:001271-9796 Yes
zebu cattle Bos indicus OMIA:001271-9915 Yes

Genes

Each gene OMIA records for a species entry, and the human gene it reaches through Ensembl's orthologs.

Species Animal gene Human gene Ortholog
domestic cattle ACAN aggrecan NCBI Gene 280985 ACAN Ensembl one to one
horse ACAN aggrecan NCBI Gene 100033876 Ensembl does not know this NCBI Gene identifier.
zebu cattle ACAN aggrecan NCBI Gene 280985 The gene belongs to a different species than the entry.

Human diseases

Two routes lead from an OMIA group to a Mondo human disease: OMIA's own Mondo link, and the group's OMIM numbers through Mondo's cross-references.

Mondo disease Name Found by
MONDO:0100462 short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans A rare genetic skeletal disorder characterized clinically by abnormal chondro-skeletal development, disproportionate short stature and skeletal deformation mainly affecting the knees, hips, ankles and elbows with onset generally in late childhood or adolescence. OMIA's OMIM numbers
MONDO:0013014 spondyloepimetaphyseal dysplasia, aggrecan type A spondyloepimetaphyseal dysplasia caused by biallelic variation in ACAN gene, characterized by severe short stature, facial dysmorphism and characteristic radiographic findings. OMIA's OMIM numbers
MONDO:0012019 spondyloepiphyseal dysplasia, Kimberley type A spondyloepiphyseal dysplasia caused by a single allele variation in ACAN gene, characterized by short stature and premature degenerative arthropathy. OMIA's OMIM numbers

Target evidence

Each Open Targets association between one of the group's human genes and one of its human diseases, with its overall score and the score for each kind of evidence.

Human gene Human disease Score Evidence Kinds of evidence
ACAN spondyloepimetaphyseal dysplasia, aggrecan type 0.75 99 Genetic association 0.80 Genetic literature 0.80 Animal model 0.49 Literature 0.02
ACAN spondyloepiphyseal dysplasia, Kimberley type 0.74 95 Genetic association 0.82 Genetic literature 0.77 Animal model 0.49 Literature 0.12

Drugs

No ChEMBL drug acts on a human gene of the group's target evidence.